Breaking Biological Barriers: Engineering Nanocarriers for Efficient Drug and Gene Delivery through Nano-Bio Interfaces and Biophysical Design
Abstract
A persistent challenge in nanomedicine is achieving functional delivery of therapeutic molecules across physiological barriers. Organs impose distinct transport constraints, including the blood-brain barrier, renal filtration, hepatic sequestration, and pulmonary clearance. Although substantial effort has focused on engineering particle structure and surface chemistry, therapeutic performance also depends on dynamic interactions at the nano-bio interface. This structured critical narrative review compares how nanoparticle design variables interact with organ-specific transport mechanisms, prioritizing mechanistic primary studies and direct clinical or regulatory evidence while preserving study-specific experimental conditions. Most review papers focus on a single disease or summarize the progress of a specific nanoparticle type. In contrast, this review addresses the heterogeneity of biological filters by proposing a barrier-specific engineering framework. We evaluate diverse high-barrier environments with distinct restrictive mechanisms and describe the strategies used to overcome them in nanoparticle design. Specifically, we focus on how matching physicochemical properties to these environments can bypass physiological constraints. Using a comparative analysis methodology, we evaluate how design parameters, including size, morphology, and surface functionalization, interact with the mechanisms of major organ systems. Applying this framework across biological barriers…
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.